Literature DB >> 2405297

Levodopa-induced dyskinesia: review, observations, and speculations.

J G Nutt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2405297     DOI： 10.1212/wnl.40.2.340

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  49 in total

Review 1.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 2.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

3.  Cannabinoids and value-based decision making: implications for neurodegenerative disorders.

Authors:  Angela M Lee; Erik B Oleson; Leontien Diergaarde; Joseph F Cheer; Tommy Pattij
Journal:  Basal Ganglia       Date:  2012-07-28

4.  An ambulatory dyskinesia monitor.

Authors:  A J Manson; P Brown; J D O'Sullivan; P Asselman; D Buckwell; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-02       Impact factor: 10.154

5.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.

Authors:  A Colzi; K Turner; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

6.  A Fuzzy Inference System for Closed-Loop Deep Brain Stimulation in Parkinson's Disease.

Authors:  Carmen Camara; Kevin Warwick; Ricardo Bruña; Tipu Aziz; Francisco del Pozo; Fernando Maestú
Journal:  J Med Syst       Date:  2015-09-18       Impact factor: 4.460

7.  Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine.

Authors:  T R K Varma; S H Fox; P R Eldridge; P Littlechild; P Byrne; A Forster; A Marshall; H Cameron; K McIver; N Fletcher; M Steiger
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

Review 8.  Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review.

Authors:  Malcolm Steiger; W Jost; F Grandas; G Van Camp
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

Review 9.  Methods of managing levodopa-induced dyskinesias.

Authors:  L T Giron; W C Koller
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

10.  Unilateral vs. bilateral STN DBS effects on working memory and motor function in Parkinson disease.

Authors:  T Hershey; J Wu; P M Weaver; D C Perantie; M Karimi; S D Tabbal; J S Perlmutter
Journal:  Exp Neurol       Date:  2007-11-29       Impact factor: 5.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.